Rathan M Subramaniam
Overview
Explore the profile of Rathan M Subramaniam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
255
Citations
2951
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henson C, Abou-Foul A, Yu E, Glastonbury C, Huang S, King A, et al.
Lancet Oncol
. 2024 Jun;
25(7):e297-e307.
PMID: 38936388
Extranodal extension of tumour on histopathology is known to be a negative prognostic factor in head and neck cancer. Compelling evidence suggests that extranodal extension detected on radiological imaging is...
2.
Parihar A, Pant N, Subramaniam R
PET Clin
. 2024 Feb;
19(2):281-290.
PMID: 38403384
The clinical landscape of lymphomas has changed dramatically over the last 2 decades, including significant progress made in the understanding and utilization of imaging modalities and the available treatment options...
3.
Zhang X, Barnett E, Smith J, Wilkinson E, Subramaniam R, Zarrabi A, et al.
Int Rev Cell Mol Biol
. 2024 Feb;
383:41-66.
PMID: 38359970
Prostate cancer is the second most prevalent cancer in men globally. De novo neuroendocrine prostate cancer (NEPC) is uncommon at initial diagnosis, however, (treatment-induced) t-NEPC emerges in up to 25%...
4.
Hollenbeak C, Duan F, Subramaniam R, Taurone A, Sicks J, Lowe V, et al.
Head Neck
. 2024 Feb;
46(8):1988-1998.
PMID: 38353324
Background: This study examined the trajectory of health-related quality of life (HRQoL) for patients with clinical stage N0 HNSCC enrolled in ACRIN 6685 who underwent elective neck dissection(s). Methods: HRQoL...
5.
Subramaniam R
PET Clin
. 2024 Jan;
19(2):125-129.
PMID: 38290968
During the last 2 decades, f-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F FDG PET/CT) has transformed the clinical head and neck cancer imaging for patient management and predicting survival outcomes....
6.
7.
Khandelwal Y, Parihar A, Sistani G, Ramirez-Fort M, Zukotynski K, Subramaniam R
PET Clin
. 2024 Jan;
19(2):177-186.
PMID: 38199915
This article focuses on the role of PET/computed tomography in evaluating and managing gastric cancer and colorectal cancer. The authors start with describing the common aspects of imaging with 2-deoxy-2-F-d-glucose,...
8.
Marcus C, Muzahir S, Subramaniam R
PET Clin
. 2023 Dec;
19(2):187-196.
PMID: 38160070
Significant improvement in molecular imaging and theranostics in the management of neuroendocrine tumors (NETs) has been made in the last few decades. Somatostatin receptor-targeted PET imaging outperforms conventional, planar, and...
9.
ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals
Wallner P, Yoo D, Calais J, Escorcia F, Mari Aparici C, Michalski J, et al.
Am J Clin Oncol
. 2023 Dec;
47(4):169-176.
PMID: 38131352
Objectives: This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine, the American Radium Society, the American Society for Radiation Oncology,...
10.
Gule-Monroe M, Calle S, Policeni B, Juliano A, Agarwal M, Chow L, et al.
J Am Coll Radiol
. 2023 Dec;
20(11S):S521-S564.
PMID: 38040469
Imaging of head and neck cancer at initial staging and as part of post-treatment surveillance is a key component of patient care as it guides treatment strategy and aids determination...